Literature DB >> 30932727

Pharmaceutical immunoglobulins reduce neutrophil extracellular trap formation and ameliorate the development of MPO-ANCA-associated vasculitis.

Ryo Uozumi1,2, Risa Iguchi1, Sakiko Masuda1, Yuka Nishibata1, Daigo Nakazawa3, Utano Tomaru4, Akihiro Ishizu1.   

Abstract

Objectives: Intravenous immunoglobulin (IVIG) therapy is effective against some autoimmune diseases. We examined the effects of pharmaceutical immunoglobulins on the development of MPO-ANCA-associated vasculitis (MPO-AAV).
Methods: Peripheral blood neutrophils were pretreated with 5 mg/ml sulfo-immunoglobulins (IVIG-S) and then exposed to 100 nM phorbol myristate acetate (PMA). Thereafter, neutrophil extracellular traps (NETs) were detected by flow cytometry. Next, Wistar-Kyoto rats were given oral administration of 10 mg/kg/day propylthiouracil for 28 days and intraperitoneal (i.p.) injection of 1 μg PMA on days 0 and 7. These rats were divided into two groups: Group 1 with i.p. injection of 400 mg/kg IVIG-S on days 8-12 and Group 2 with vehicle similarly. ANCA titers were chronologically determined by indirect immunofluorescence. On day 28, all rats were killed to examine NET formation in the peritoneum and the development of AAV.
Results: IVIG-S significantly inhibited NET formation induced by PMA in vitro. NET amounts in the peritoneum in Group 1 were significantly smaller than in Group 2, and ANCA titers in Group 1 were significantly lower than in Group 2. The degree of pulmonary hemorrhage in Group 1 was also smaller than in Group 2.
Conclusion: IVIG-S reduce NET formation and ameliorate the development of MPO-AAV.

Entities:  

Keywords:  ANCA-associated vasculitis; Anti-neutrophil cytoplasmic antibody (ANCA); animal model; intravenous immunoglobulin (IVIG); neutrophil extracellular traps (NETs)

Year:  2019        PMID: 30932727     DOI: 10.1080/14397595.2019.1602292

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  11 in total

1.  Case Series of Successful Intravenous Immunoglobulin (IVIG) Treatment in 4 Pregnant Patients with Severe COVID-19-Induced Hypoxia.

Authors:  Matthew Geriak; Dominic McGrosso; David J Gonzalez; Matthew Dehner; George Sakoulas
Journal:  Am J Case Rep       Date:  2022-05-14

2.  Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019.

Authors:  George Sakoulas; Matthew Geriak; Ravina Kullar; Kristina L Greenwood; MacKenzie Habib; Anuja Vyas; Mitra Ghafourian; Venkata Naga Kiran Dintyala; Fadi Haddad
Journal:  Crit Care Explor       Date:  2020-11-16

3.  Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia.

Authors:  Matthew Geriak; Fadi Haddad; Ravina Kullar; Kristina L Greenwood; MacKenzie Habib; Cole Habib; David Willms; George Sakoulas
Journal:  Infect Dis Ther       Date:  2021-05-11

Review 4.  Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment.

Authors:  Sebastiano Cicco; Gerolamo Cicco; Vito Racanelli; Angelo Vacca
Journal:  Mediators Inflamm       Date:  2020-07-16       Impact factor: 4.711

Review 5.  Neutrophil Extracellular Traps (NETs) Take the Central Stage in Driving Autoimmune Responses.

Authors:  Esther Fousert; René Toes; Jyaysi Desai
Journal:  Cells       Date:  2020-04-08       Impact factor: 6.600

Review 6.  Neutrophil Extracellular Traps: A Potential Therapeutic Target in MPO-ANCA Associated Vasculitis?

Authors:  Kim M O'Sullivan; Stephen R Holdsworth
Journal:  Front Immunol       Date:  2021-03-15       Impact factor: 7.561

Review 7.  Neutrophil Extracellular Traps in ANCA-Associated Vasculitis and Interstitial Lung Disease: A Scoping Review.

Authors:  Miriana d'Alessandro; Edoardo Conticini; Laura Bergantini; Paolo Cameli; Luca Cantarini; Bruno Frediani; Elena Bargagli
Journal:  Life (Basel)       Date:  2022-02-20

Review 8.  High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects.

Authors:  Xiaosheng Liu; Wei Cao; Taisheng Li
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561

Review 9.  Immunopathogenesis of ANCA-Associated Vasculitis.

Authors:  Andreas Kronbichler; Keum Hwa Lee; Sara Denicolò; Daeun Choi; Hyojeong Lee; Donghyun Ahn; Kang Hyun Kim; Ji Han Lee; HyungTae Kim; Minha Hwang; Sun Wook Jung; Changjun Lee; Hojune Lee; Haejune Sung; Dongkyu Lee; Jaehyuk Hwang; Sohee Kim; Injae Hwang; Do Young Kim; Hyung Jun Kim; Geonjae Cho; Yunryoung Cho; Dongil Kim; Minje Choi; Junhye Park; Junseong Park; Kalthoum Tizaoui; Han Li; Lee Smith; Ai Koyanagi; Louis Jacob; Philipp Gauckler; Jae Il Shin
Journal:  Int J Mol Sci       Date:  2020-10-03       Impact factor: 5.923

Review 10.  Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease.

Authors:  Maria Giovanna Danieli; Mario Andrea Piga; Alberto Paladini; Eleonora Longhi; Cristina Mezzanotte; Gianluca Moroncini; Yehuda Shoenfeld
Journal:  Scand J Immunol       Date:  2021-09-16       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.